Risk of flare and damage accrual after tapering glucocorticoids in modified serologically active clinically quiescent patients with systemic lupus erythematosus: a multinational observational cohort study.
Yasuhiro KatsumataEisuke InoueMasayoshi HarigaiJiacai ChoWorawit LouthrenooAlberta Y HoiVera GolderChak Sing LauAisha LateefYi-Hsing ChenShue-Fen LuoYeong-Jian Jan WuLaniyati HamijoyoZhanguo LiSargunan SockalingamSandra NavarraLeonid ZamoraYanjie HaoZhuoli ZhangMadelynn ChanShereen OonKristine NgJun KikuchiTsutomu TakeuchiFiona GoldblattSean O'NeillNicola TugnetAnnie Hui Nee LawSang-Cheol BaeYoshiya TanakaNaoaki OhkuboSunil KumarRangi Kandane-RathnayakeMandana NikpourEric F Morandnull nullPublished in: Annals of the rheumatic diseases (2024)
In mSACQ patients, tapering GCs was not associated with increased flare risk. Antimalarial use was associated with decreased flare risk. Tapering GCs protected mSACQ patients treated with >5 mg/day of prednisolone against damage accrual. These findings suggest that cautious GC tapering is feasible and can reduce GC use in mSACQ patients.